- Home
- CATO vs ALXO Comparison
CATO vs ALXO Comparison
Compare CATO & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CATO | ALXO |
|---|---|---|
| Founded | 1946 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 59.2M | 68.3M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | CATO | ALXO |
|---|---|---|
| Price | $3.43 | $1.18 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $3.30 |
| AVG Volume (30 Days) | 54.0K | ★ 210.1K |
| Earning Date | 11-20-2025 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $660,062,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.19 | $0.40 |
| 52 Week High | $4.92 | $2.27 |
Technical Indicators
Market Signals| Indicator | CATO | ALXO |
|---|---|---|
| Relative Strength Index (RSI) | 56.23 | 42.28 |
| Support Level | $3.36 | $1.07 |
| Resistance Level | $3.61 | $1.56 |
| Average True Range (ATR) | 0.19 | 0.12 |
| MACD | 0.06 | 0.00 |
| Stochastic Oscillator | 70.53 | 21.43 |
Price Performance
Historical ComparisonAbout CATO Cato Corporation (The)
The Cato Corp operates as a specialty retailer of fashion apparel and accessories in the southeastern United States. Its primary objective is to be the fashion specialty retailer for fashion and value in its markets. The company operates through the following business segments: Retail and Credit. The Retail segment which generates the majority of revenue offers fashion specialty stores. The Credit segment involves credit card services.
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.